ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

  

Authors:	Attard, G.; De Bono, J. S.; Li, W.; Molina, A.; Griffin, T. W.; Kheoh, T. S.; Ricci, D. S.; Zelinsky, K.; Rathkopf, D. E.; Scher, H. I.; Ryan, C. J.
Abstract Title:	ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Meeting Title:	49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	31
Issue:	15 Suppl.
Meeting Dates:	2013 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2013-05-20
Language:	English
ACCESSION:	WOS:000335419601605
PROVIDER:	wos
DOI:	10.1200/jco.2013.31.15_suppl.5004
Notes:	Meeting Abstract: 5004 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/128614